109 related articles for article (PubMed ID: 35702555)
1. Bone Marrow Carcinomatosis in a Stage IV Breast Cancer Patient Treated by Letrozole as First-Line Endocrine Therapy.
Nakagawa T; Hayashi K; Ogawa A; Oda G; Onishi I; Yamamoto M; Mori M; Fujioka T; Ishikawa T; Okamoto K; Uetake H
Case Rep Oncol; 2022; 15(1):436-441. PubMed ID: 35702555
[TBL] [Abstract][Full Text] [Related]
2. [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Nakamura A; Shigekawa T; Asakawa H; Park K; Baba N
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1251-1254. PubMed ID: 34657057
[TBL] [Abstract][Full Text] [Related]
3. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
Reinert T; Barrios CH
Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
[TBL] [Abstract][Full Text] [Related]
4. Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy.
Yamaguchi T; Masumoto M; Sakurai U; Nakane M
Case Rep Oncol; 2020; 13(1):193-199. PubMed ID: 32231544
[TBL] [Abstract][Full Text] [Related]
5. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
[TBL] [Abstract][Full Text] [Related]
7. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Turner NC; Finn RS; Martin M; Im SA; DeMichele A; Ettl J; Diéras V; Moulder S; Lipatov O; Colleoni M; Cristofanilli M; Lu DR; Mori A; Giorgetti C; Iyer S; Bartlett CH; Gelmon KA
Ann Oncol; 2018 Mar; 29(3):669-680. PubMed ID: 29342248
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
9. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
12. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Kopp HG; Krauss K; Fehm T; Staebler A; Zahm J; Vogel W; Kanz L; Mayer F
Anticancer Res; 2011 Nov; 31(11):4025-30. PubMed ID: 22110237
[TBL] [Abstract][Full Text] [Related]
14. Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis.
Zhang T; Feng F; Zhao W; Tian J; Yao Y; Zhou C; Dong S; Wang C; Zang C; Lv Q; Sun C
Onco Targets Ther; 2018; 11():2647-2656. PubMed ID: 29780257
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
16. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
17. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
18. A case report of symptomatic gallbladder disease in the setting of peritoneal carcinomatosis originating from invasive lobular carcinoma of the breast.
Brinkman D; Misra S; Aydin N
Int J Surg Case Rep; 2016; 24():60-2. PubMed ID: 27180323
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Zhang J; Huang Y; Wang C; He Y; Zheng S; Wu K
Medicine (Baltimore); 2017 Aug; 96(33):e7846. PubMed ID: 28816986
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
